As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.
Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.
He kicked things off emphatically with a dominant Senior Bowl showing against upper echelon, NFL bound competition. Then at the Combine he was measured with class-leading 35” arms and an 85 ¾” ...
Even though the final game left a bitter taste in their mouths, the New England Patriots have plenty to feel good about coming out of the 2025 NFL season. Having won just eight total games the ...
Q4 2025 Earnings Call February 26, 2026 4:30 PM ESTCompany ParticipantsMike Brophy - Chief Financial OfficerSteve Chapman - CEO ...
Experts demystify everything you need to know about these beauty supplements and why it's time to consider them ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
Cuba is facing its most serious challenge since the fall of the USSR, as the United States tightens its blockade against the island, following the kidnapping of Venezuelan president ...
(DecisionDx-Melanoma, TissueCypher) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast ...
When Max Voehl auditioned to play a young boy in the musical “Wonder,” he sensed he was playing a version of himself on stage ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec.
Ionis Pharmaceuticals, Inc. today announced new data to be presented for DAWNZERAtm (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results